• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Cue Biopharma Inc (NQ: CUE )

    1.650 UNCHANGED
    Streaming Delayed Price Updated: 4:00 PM EDT, May 13, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 0
    Open 1.650
    Bid (Size) 1.580 (1)
    Ask (Size) 2.620 (1)
    Prev. Close 1.650
    Today's Range 1.650 - 1.650
    52wk Range 1.303 - 4.890
    Shares Outstanding 44,959,548
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    CUE Stock Earnings: Cue Biopharma Beats EPS, Beats Revenue for Q1 2024
    CUE stock results show that Cue Biopharma beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. 
    Via InvestorPlace
    Cue Biopharma Reports First Quarter 2024 Financial Results and Recent Business Highlights
    From Cue Biopharma, Inc.
    Via GlobeNewswire

    Performance

    YTD
    -40.65%
    -40.65%
    1 Month
    +3.45%
    +3.45%
    3 Month
    -35.29%
    -35.29%
    6 Month
    -30.96%
    -30.96%
    1 Year
    -62.92%
    -62.92%

    More News

    Read More
    Cue Biopharma to Present at the 20th Annual PEGS Boston Summit
    From Cue Biopharma, Inc.
    Via GlobeNewswire
    Forecasting The Future: 4 Analyst Projections For Cue Biopharma
    Via Benzinga
    Cue Biopharma Inc. (NASDAQ: CUE) Leading the Way in Wednesday Trading Based on Percentage Gain
    Via Investor Brand Network
    Cue Biopharma to Participate in Fireside Chat at The Citizens JMP Life Sciences Conference
    From Cue Biopharma, Inc.
    Via GlobeNewswire
    12 Health Care Stocks Moving In Thursday's After-Market Session
    Via Benzinga
    Cue Biopharma to Present at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
    From Cue Biopharma, Inc.
    Via GlobeNewswire
    Cue Biopharma Reports Fourth Quarter and Full Year 2023 Financial Results and Updated Business Highlights
    From Cue Biopharma, Inc.
    Via GlobeNewswire
    CUE Stock Earnings: Cue Biopharma Misses EPS, Beats Revenue for Q4 2023
    Via InvestorPlace
    Cue Biopharma to Host Business Update Call and Webcast
    From Cue Biopharma, Inc.
    Via GlobeNewswire
    Why Clover Health Investments Shares Are Trading Higher By 11%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
    Via Benzinga
    Cue Biopharma’s Lead Clinical Asset, CUE-101, to be Featured at the 2024 Multi-disciplinary Head and Neck Cancers Symposium
    From Cue Biopharma, Inc.
    Via GlobeNewswire
    Cue Biopharma to Present Corporate Update at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
    From Cue Biopharma, Inc.
    Via GlobeNewswire
    12 Health Care Stocks Moving In Monday's After-Market Session
    Via Benzinga
    CUE Stock Earnings: Cue Biopharma Beats EPS, Beats Revenue for Q3 2023
    Via InvestorPlace
    Cue Biopharma to Present at the JMP Securities Hematology and Oncology Summit
    From Cue Biopharma, Inc.
    Via GlobeNewswire
    Cue Biopharma Reports Third Quarter 2023 Financial Results and Recent Business Highlights
    From Cue Biopharma, Inc.
    Via GlobeNewswire
    Cue Biopharma to Present at Three Upcoming Investor Healthcare Conferences in November
    From Cue Biopharma, Inc.
    Via GlobeNewswire
    Cue Biopharma Presents New Positive Data from Phase 1 Trials of CUE-101 in Head and Neck Cancer and CUE-102 in Wilms’ Tumor 1 Positive Cancers at SITC 2023
    From Cue Biopharma, Inc.
    Via GlobeNewswire
    Cue Biopharma to Host Business Update Call and Webcast
    From Cue Biopharma, Inc.
    Via GlobeNewswire
    Cue Biopharma Announces Upcoming Scientific Presentations at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting
    From Cue Biopharma, Inc.
    Via GlobeNewswire
    Cue Biopharma Announces Completion of Patient Enrollment in Phase 1b Study of CUE-101 in Combination with KEYTRUDA®
    From Cue Biopharma, Inc.
    Via GlobeNewswire
    The Truth About IPO Investing
    Via Talk Markets
    Topics Initial Public Offering
    Exposures Securities Market
    Cue Biopharma And 2 Other Stocks Under $3 Insiders Are Buying
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.